Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dl?

Size: px
Start display at page:

Download "Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dl?"

Transcription

1 Postgraduate Medicine ISSN: (Print) (Online) Journal homepage: Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dl? Gary Ruoff & N. Lawrence Edwards To cite this article: Gary Ruoff & N. Lawrence Edwards (2016) Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dl?, Postgraduate Medicine, 128:7, , DOI: / To link to this article: Accepted author version posted online: 10 Aug Published online: 25 Aug Submit your article to this journal Article views: 1273 View related articles View Crossmark data Citing articles: 2 View citing articles Full Terms & Conditions of access and use can be found at

2 POSTGRADUATE MEDICINE, 2016 VOL. 128, NO. 7, CLINICAL FEATURE REVIEW Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dl? Gary Ruoff a and N. Lawrence Edwards b a Department of Family Practice, Michigan State University, Kalamazoo, MI, USA; b Department of Medicine, University of Florida, Gainesville, FL, USA ABSTRACT Gout is a progressive, painful, debilitating form of inflammatory arthritis. It is caused by factors that elevate the concentration of serum uric acid (sua), leading to hyperuricemia (sua >6.8 mg/dl). Continued elevated sua can result in monosodium urate (MSU) crystal deposition in joints and soft tissues, and can cause acute and chronic inflammation. The prevalence of hyperuricemia and gout has increased over the last few decades, likely due to an aging population, changes in lifestyles and diet, and an increase in gout-associated comorbidities. Untreated or improperly treated gout can lead to chronic manifestation of the disease, including persistent inflammation, increased number of flares, development of tophi, and structural joint damage. Data show that even when patients are asymptomatic, ongoing inflammation and subsequent damage occurs locally at the joint and systemically. The aim of long-term treatment of gout is to reduce sua levels to <6 mg/dl, which is below the saturation point of MSU (6.8 mg/dl), to inhibit formation of new crystals and to promote dissolution of existing crystals. Gout treatment should improve disease outcomes by eliminating gout flares, inducing longterm resolution of tophi, and more effectively managing comorbidities, many of which are associated with hyperuricemia. A number of studies have demonstrated that treating to the target of <6 mg/dl, by using effective therapies to lower sua, results in reduction in the incidence of gout flares as well as shrinkage and eventual disappearance of tophi. Gout is often poorly managed due to a number of factors including lack of physician and patient adherence to treatment guidelines. Patients need to be educated about their diagnosis and management of the disease, such as the influence of diet and the importance of compliance with long-term treatment. With treatment, regular sua monitoring, and patient adherence, gout is a curable disease. ARTICLE HISTORY Received 4 March 2016 Accepted 4 August 2016 Published online 26 August 2016 KEYWORDS Gout; serum uric acid; monosodium urate; inflammatory arthritis; treatment guidelines; hyperuricemia; joint damage; joint erosion; MSU crystals; tophi Methods PubMed and Google Scholar databases were searched to identify clinical trials and review articles on the epidemiology, disease mechanism, history, clinical presentation, and treatment and management of gout. The search also identified previously recommended guidelines which were incorporated into the review. Search terms included, but were not limited to, gout, hyperuricemia, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), comorbidity, flare, adherence, epidemiology, serum uric acid (sua), monosodium urate (MSU), tophi, joint damage, joint erosion, <6 mg/dl, MSU crystal formation, and individual drug names and classes of treatments of interest. Both authors actively participated in the drafting and editing of the paper and offered comprehensive discussions regarding the content. Gout background and epidemiology Gout is a progressive, painful, debilitating form of inflammatory arthritis that has been affecting man since antiquity [1 3]. It is caused by factors that elevate the concentration of sua, leading to hyperuricemia [2,4]. Continued elevated sua can result in MSU crystal deposition throughout the body, including joints, soft tissues, cartilage, and organs (e.g. kidneys) [5]. MSU crystals trigger the periodic occurrence of painful, acute, inflammatory flares [1,2]. If hyperuricemia persists, the acute gout flares may be superseded by long-term, chronic, tophaceous gout with bone and cartilage destruction [1,2]. Gout is one of the most common forms of inflammatory arthritis among men. In the USA, about 8.3 million adults (4%) are affected by gout and 43.3 million (21%) by hyperuricemia [6]. Both occur with greater frequency in adults than other wellknown, chronic, joint- or pain-related debilitating diseases such as fibromyalgia (5.0 million) [7], rheumatoid arthritis (1.5 million) [8], and psoriatic arthritis (0.5 million) [9]. Gout and other crystal arthropathies accounted for 1.5% of the 1.2 million nonfederal, short-stay hospitalizations in 2007 [1]. All-cause medical expenditures in persons with gout are estimated to total about $11,663 per person per year, and the direct burden for new gout in the USA may be greater than $27 million per year [1,10]. In addition, gout is a source of significant personal burden for patients. Among those with inadequately controlled gout, the condition is associated with significant functional disability, loss of work productivity, reduction in social activity, and poor health-related quality of life [11 13]. In fact, the work loss CONTACT N. Lawrence Edwards larry.edwards@medicine.ufl.edu Department of Medicine, University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL , USA 2016 Informa UK Limited, trading as Taylor & Francis Group

3 POSTGRADUATE MEDICINE 707 observed with gout is similar to that seen with rheumatoid arthritis [8,11]. The prevalence of gout and hyperuricemia has increased considerably over the last 25 years [6,14]. This increase may be due to an aging population, changes in lifestyle and diet (e.g. higher intake of fructose-containing soft drinks and alcoholic beverages, such as beer), and an increasing prevalence of comorbidities associated with hyperuricemia and gout, such as obesity, hypertension, widespread use of thiazide diuretics, and chronic kidney disease (CKD) [14 17]. Other factors associated with hyperuricemia and gout include metabolic syndrome, congestive heart failure, and organ transplantation [18]. In fact, evidence suggests that increased sua levels may play a role in the development of metabolic syndrome, type 2 diabetes, and hypertension [19]. A history of gout is also an independent risk factor for cardiovascular disease, possibly due to increased systemic inflammation [20]. Use of sua-lowering therapy improved blood pressure and had a cardiovascular protective effect [19]. Hyperuricemia has also been shown to be predictive of CKD; however, it is unclear whether elevated sua levels have a causal role in the development of kidney disease [20]. Similarly, the precise role of uric acid in the development of cardiovascular disease is not clear [19]. Furthermore, age and genetic factors can predispose an individual to developing gout. Genetic variation in solute carrier family 2 member 9 (SLC2A9) and 11 (SLC22A11); solute carrier family member 17, member 1 (SLC17A1); coding PDZ domaincontaining 1 (PDK-Z1); and ATP-binding cassette, subfamily G, member 2 (ABCG2) have been implicated in increasing the risk of gout [21,22]. Asymptomatic hyperuricemia can begin during puberty in boys, but is usually delayed until menopause in women [3]. Estrogen has a uricosuric effect, making the disease less common among premenopausal women [14,23]. Gout commonly develops in men between 40 and 60 years of age after many (approximately 20 30) years of hyperuricemia [3]. Before the age of 65 years, men have a fourfold greater incidence of gout than women (about 4 per 1000 persons in men compared with 1 per 1000 persons in women) [23,24]. After 65 years of age, prevalence increases for both men and women at a more comparable rate, with incidence about threefold higher in men [24]. Presentation and characterization of gout Classically, gout has been described as occurring in three stages: asymptomatic hyperuricemia, acute intermittent gout (flares), and advanced or chronic gout (Figure 1) [25,26]. A recent modification of this staging, however, has been proposed by Dalbeth and Stamp (2014) that includes four stages, with the period of asymptomatic hyperuricemia subdivided into two separate stages: Stage A (hyperuricemia without detectable MSU crystal deposition); Stage B (hyperuricemia with MSU crystal deposition but no signs or symptoms of gout); Stage C (MSU crystal deposition with prior or current symptoms of a gout flare); and Stage D (advanced gout requiring a specialist s intervention) [27]. Hyperuricemia is defined as sua levels >6.8 mg/dl (404 µmol/l) and no symptoms from crystal deposition [28,29]. Of note, each laboratory calculates its own sua threshold for hyperuricemia, often defined as the mean sua plus 2 standard deviations for their local healthy population, and calculated separately according to sex [30,31]. Therefore, an sua level in what an individual laboratory considers the normal range may still reflect levels in joint tissues that are above the point for MSU crystal formation [31]. The rate at which a person progresses from asymptomatic hyperuricemia to chronic advanced gout varies by individual and is dependent upon numerous factors, the most important of which is the degree of increase in the concentration of sua (Figure 2) [3,32,33]. Of all patients with asymptomatic hyperuricemia, only about 15 20% will develop gout [3]. In these patients, MSU Figure 1. Diagram showing the path from hyperuricemia to structural joint damage. Long-standing hyperuricemia may lead to monosodium urate (MSU) deposits. Hyperuricemia is typically asymptomatic and is often associated with subclinical inflammation and bone erosion. Crystal shedding into the joint can cause Intermittent, acute inflammation and a gout flare-up. Continued crystal deposition can result in chronic manifestation of the disease, including persistent inflammation, increased number of flares, development of tophi, and structural joint damage. Adapted from Adv Ther, A review of uric acid, crystal deposition disease, and gout, volume 32, 2015, Perez-Ruiz F, et al, Figure 1: Diagram showing the path from hyperuricemia to structural joint damage on page 32, with permission of Springer ( 2014) [26].

4 708 G. RUOFF AND N. L. EDWARDS Etiology Figure 2. Five-year cumulative incidence of gout according to sua level in men in the Normative Aging Study [33]. Reproduced with permission from Roddy E and Doherty M: Arthritis Res Ther 2010;12(6):223. [32]. crystal deposition, subclinical inflammation, and bone erosion can occur [3,18,26,33,34]. The MSU crystals form small lattice structures on the surface of synovial lining and cartilage [3]. The fact that not all patients with hyperuricemia develop gout suggests that other factors may contribute to the formation of crystals and the ability of formed crystals to trigger flares [26]. MSU deposition is a precursor to gout, but it is unclear whether MSU crystals in patients with asymptomatic hyperuricemia predict development of clinically apparent gout [26]. After a prolonged period of hyperuricemia, the shedding of asymptomatic, preformed crystals from the cartilage surface into the joint triggers inflammation characteristic of an acute flare [26,34]. The first manifestation of acute gout is an attack of synovitis typically affecting a single peripheral joint, most often the first metatarsophalangeal joint [35]. Other joints commonly affected include the ankles, knees, mid-tarsal joints, fingers, elbows, and wrists [35,36]. Acute attacks are characterized by the sudden onset of extreme pain, which typically takes less than 24 h to peak in intensity (Table 1) [35,36]. Flares are also associated with swelling, heat, tenderness, and erythema [35,36]. Acute gouty flares are self-limiting, with symptoms resolving in about 2 weeks [26,36]. Although acute flares appear episodic in nature, ongoing damage during intercritical asymptomatic periods occurs due to continuing MSU crystal deposition and inflammation [26,37,38]. This continuing damage may not be apparent in normal plain radiographs; however, the destructive arthropathy can be detected by more advanced imaging procedures, such as dual-energy computed tomography (DECT), computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (Figure 3) [39,40]. Untreated or improperly treated crystal deposition can lead to chronic manifestation of the disease, including persistent inflammation, increased number of flares, development of tophi, and structural joint damage [26]. Tophi can cause chronic inflammation and erosive arthritis [16]. Chronic gout typically develops after 10 or more years of acute episodic gout, and is apparent when the pain-free intermittent periods disappear [3]. Hyperuricemia is the most important risk factor for gout [33,34]. In vitro, at 37 C and ph 7.4, levels of uric acid above 6.8 mg/dl result in crystal formation and aggregation [41 43]. Solubility of a substance (a solute) is a measure of how well one substance dissolves into another (Figure 4). A solute can fully dissolve in a solution that contains less than the maximum amount of solute that can be dissolved. A saturated solution contains as much solute as it possibly can dissolve, and a supersaturated solution contains more solute than can be dissolved, resulting in crystal formation. As sua levels rise, the blood and body fluids become supersaturated, causing crystals to form in synovial fluids, soft tissues, and organs [5,43,44]. Crystal deposition is reversible, and crystals can dissolve when the concentration of sua is reduced to levels <6 mg/dl [43,45]. The importance of maintaining sua levels below 6.8 mg/dl is made evident by the observation that the incidence of gout increases with higher levels of sua, starting at between 6.0 and 6.9 mg/dl (Figure 2) [3,32,33]. One study found that the annual incidence of gouty arthritis for patients with sua >9 mg/dl was 4.9%, compared with 0.5% for urate levels of mg/dl and 0.1% for urate levels <7.0 mg/dl [33]. Another study found that the 5-year incidence rate of gout was 0.6% in patients with sua levels <7 mg/dl and about 30% for patients with sua levels >10 mg/dl [46]. Uric acid levels are controlled by the rate of urate production and the elimination of urate via the kidneys and the gastrointestinal tract. In about 90% of patients with hyperuricemia, sua levels are elevated mainly due to inefficient renal excretion rather than overproduction of uric acid [3]. About one-third of uric acid comes from exogenous sources, such as diet (alcohol/beer, red meat, seafood) [47,48]. The other twothirds derive from endogenous production via the degradation of purines, such as DNA and RNA [48,49]. In humans, urate is produced by the conversion of hypoxanthine to xanthine, which is subsequently converted to uric acid by an enzyme called xanthine oxidase [3]. Most mammals possess an additional enzyme, uric acid oxidase, that converts uric acid into a soluble end product called allantoin that is readily eliminated in urine [3]. The ability of humans and other higher primates to make uric acid oxidase was lost during evolution, and consequently, humans are prone to uric acid accumulation [3]. The gastrointestinal tract eliminates about 20% of urate, while the rest is excreted by the kidney [50]. The majority of uric acid (about 98 99%) circulates in the blood as ionized urate, and due to the high concentration of sodium in the extracellular compartment, urate is primarily present as MSU [15,51]. Guideline recommendations for sua levels The primary aim of treatment for gout is to lower sua [52]. Several guidelines, such as those published by the ACR [53] and EULAR [31,54] (plus others, such as the American Society of Clinical Rheumatologists [ASCR] [28], the 3Es [Evidence, Expertise, Exchange] Initiative [55], Japanese Society of Gout and Nucleic Acid Metabolism [JSGNM] [56], and the Dutch College of General Practitioners [DCGP] [57]) recommend a

5 POSTGRADUATE MEDICINE 709 Table 1. The ACR/EULAR gout classification criteria (reproduced with permission from Neogi et al. [36]. Steps Categories Score* Step 1: Entry criterion (only apply criteria below to those meeting this entry criterion) At least one episode of swelling, pain, or tenderness in a peripheral joint or bursa Step 2: Sufficient criterion (if met, can classify as gout without applying criteria below) Presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus Step 3: Criteria (to be used if sufficient criterion not met) Clinical Pattern of joint/bursa involvement during symptomatic episode(s) ever Ankle or mid-foot (as part of monoarticular or oligoarticular episode without involvement of the first metatarsophalangeal 1 joint Involvement of the first metatarsophalangeal joint (as part of monoarticular or oligoarticular episode) Characteristics of symptomatic episode(s) ever Erythema overlying affected joint (patient reported or physician observed) One characteristic 1 Cannot bear touch or pressure to affected joint Two characteristics 2 Great difficulty walking or inability to use affected joint Three characteristics 3 Time course of episode(s) ever (presence [ever] of 2, irrespective of antiinflammatory treatment) Time to maximal pain <24 h One typical episode 1 Resolution of symptoms in 14 d Recurrent typical episodes 2 Complete resolution (to baseline level) between symptomatic episodes Clinical evidence of tophus Draining or chalk-like subcutaneous nodule under transparent skin, often with overlying vascularity, located in typical locations: joints, ears, olecranon bursae, finger pads, tendons (e.g. Achilles) Laboratory Serum urate : measured by the uricase method. Ideally should be scored at a time when the patient was not receiving uratelowering therapy and it was >4 weeks from the start of an episode (i.e. during intercritical period); if practicable, retest under those conditions. The highest value irrespective of timing should be scored Present 4 <4 mg/dl (<0.24 μmol/l) 6 <8 mg/dl (0.36 <0.48 μmol/l) 8 <10 mg/dl (0.48 <0.60 μmol/l) 10 mg/dl ( 0.60 μmol/l) Synovial fluid analysis of a symptomatic ever joint or bursa MSU negative 2 Imaging # Imaging evidence of urate deposition in symptomatic (ever) joint or bursa: ultrasound evidence of double-contour sign or DECT demonstrating urate deposition** Present (either modality) 4 Imaging evidence of gout-related joint damage: conventional radiography of the Present 4 hands and/or feet demonstrates at least one erosion DECT: dual-energy computed tomography; MSU: monosodium urate. *The higher the score, the greater likelihood of gout. A web-based calculator can be accessed at and through the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) websites. Symptomatic episodes are periods of symptoms that include any swelling, pain, and/or tenderness in a peripheral joint or bursa. If serum urate level is <4 mg/dl (<0.24 mmol/l), subtract 4 points; if serum urate level is 4 mg/dl to <6 mg/dl ( 0.24 <0.36 mmol/l), score this item as 0. Should be assessed by a trained observer. If polarizing microscopy of synovial fluid from a symptomatic (ever) joint or bursa by a trained examiner fails to show MSU crystals, subtract 2 points. If synovial fluid was not assessed, score this item as 0. # If imaging is not available, score these items as 0. Hyperechoic irregular enhancement over the surface of the hyaline cartilage that is independent of the insonation angle of the ultrasound beam (note: falsepositive double-contour sign [artifact] may appear at the cartilage surface but should disappear with a change in the insonation angle of the probe). **Presence of color-coded urate at articular or periarticular sites. Images should be acquired using a DECT scanner, with data acquired at 80 kv and 140 kv and analyzed using gout-specific software with a two-material decomposition algorithm that color-codes urate. A positive scan is defined as the presence of colorcoded urate at articular or periarticular sites. Nail bed, submillimeter, skin, motion, beam hardening, and vascular artifacts should not be interpreted as DECT evidence of urate deposition. Erosion is defined as a cortical break with sclerotic margin and overhanging edge, excluding distal interphalangeal joints and gull wing appearance target sua level of <6 mg/dl (360 µmol/l). In some cases, a lower target (<5 mg/dl) may be recommended to more rapidly improve gout signs and symptoms in patients with more severe disease [53,54]. In contrast, the British Society of Rheumatology recommends the lower (<5 mg/dl) sua target for all patients with gout [58]. The idea behind treating to a target of <6 mg/dl and achieving lifelong maintenance of this level is to lower the concentration of sua well below its saturation point and to provide some margin to accommodate the influence of natural fluctuations in uric acid levels. Lower sua levels also increase the resolution rate of tophaceous deposits (Figure 5) [59]. Gout treatment should improve disease outcomes by eliminating gout flares, inducing long-term resolution of tophi, and more effectively managing comorbidities, many of which are associated with hyperuricemia [31,53]. There is growing evidence of the association of gout with several chronic diseases, including cardiovascular disease, and data exist that indicate gout treatment may improve some of these comorbidities [60,61]. The ACR recommends both nonpharmacologic and pharmacologic approaches to treatment after first establishing the diagnosis of gout (Figure 6) [53]. Patient education is an important component of treatment and should include information on lifestyle adjustments, treatment objectives, and management of comorbidities [52,53]. Patients should be encouraged to lose weight and be cautioned about consumption of excessive amounts of foods with high purine content, such as organ meats, shell fish, and alcohol (especially beer), as well as foods containing high fructose corn syrup, all of which could trigger a flare [14,20]. However, diet change

6 710 G. RUOFF AND N. L. EDWARDS Figure 3. Dual-energy computed tomography (DECT) images of ankle and foot (a, b) showing MSU crystal deposition in green color (arrows) and corresponding CT images (c, d) showing erosions (arrowheads). Reproduced with permission from Chowalloor PV, et al: Ther Adv Musculoskelet Dis 2014;6(4): [40]. Figure 4. Solubility of a substance (a solute) is the amount of that substance that will dissolve in a given amount of solvent; or it is a measure of how well one substance dissolves into another. A solute can fully dissolve in a solution that has less than the maximum amount of solute that can be dissolved. A saturated solution contains as much solute as it possibly can dissolve. A supersaturated solution contains more solute than can be dissolved, increasing the potential for crystal formation. alone, although beneficial, is rarely sufficient to lower sua levels to the degree necessary to prevent acute or chronic disease [52,62]. Physicians should consider all causes of hyperuricemia both exogenous and endogenous for all gout patients, and evaluate certain disorders that are associated with hyperuricemia and gout, such as obesity, metabolic Figure 5. Mean serum urate levels versus velocity of tophi reduction. Reproduced with permission from Perez-Ruiz F, et al: Arthritis Rheum 2002;47 (4): [59]. syndrome, type 2 diabetes, hypertension, and CKD [52,53]. The ACR treatment guidelines also advocate consideration of the removal or replacement of nonessential prescription drugs (e.g. thiazide and loop diuretics, niacin, and calcineurin inhibitors), when appropriate, which are known to elevate sua [53]. Following these initial steps, ACR recommends that a patient be evaluated for the use of urate-lowering therapy (ULT). A patient is considered a candidate if he/she has at least one of the following: tophus or tophi (verified by clinical examination or imaging study); 2 gout flares per year; stage 2 or worse CKD; or past urolithiases [53]. If pharmacologic ULT is

7 POSTGRADUATE MEDICINE 711 Figure 6. Baseline ACR recommendations and overall strategy for treating and managing patients with gout. Data from Khanna D, et al: Arthritis Care Res (Hoboken) 2012;64(10): [53]. indicated, the patient should be treated to achieve an sua target of <6 mg/dl [53]. First-line pharmacologic therapies are xanthine oxidase inhibitors (e.g. allopurinol or febuxostat), or if necessary due to poor tolerability or contraindications, an alternative therapy (e.g. probenecid) can be used instead [53]. If needed, ACR guidelines recommend the addition of probenecid to a xanthine oxidase inhibitor [53]. Pegloticase can be considered if treatment goals are not achieved and there is continuing disease activity [53]. If the target level of <6 mg/dl is not achieved, the dose of the ULT should be increased [53]. When ULT is started, anti-inflammatory prophylactic treatment should also be initiated to reduce the increased risk of acute gouty attacks during the early phase (first 6 months) of treatment [53]. Nonsteroidal anti-inflammatory drugs and low-dose colchicine are options for prophylactic therapy [53]. Once the sua target of <6 mg/dl is achieved continuously [53], the dose of ULT should be maintained indefinitely with ongoing monitoring of sua levels twice yearly [53]. Anti-inflammatory prophylaxis should be maintained for at least 6 months after the target is achieved, or 3 months after achieving target sua in patients without tophi, or 6 months in patients with tophi [53]. It may be necessary to reduce sua levels to <5 mg/dl for patients with advanced disease and tophaceous deposits [53]. After all symptoms have resolved, ACR guidelines recommend continuing all measures and therapies needed to keep the patient s sualevels<6mg/dl[53]. In patients with more advanced disease, the primary care provider (PCP) may consider referral to a specialist, such as a rheumatologist, for cases of unclear etiology of hyperuricemia, refractory signs and symptoms of gout, lack of tolerability to standard therapy, or difficulty in reaching the sua level target goal of <6 mg/dl [53]. Reasoning behind the sua target goal of <6 mg/dl For patients whose sua levels are not lowered sufficiently, gout will continue to be a chronic, progressive disease [26]. Achieving a lower level of sua can help prevent further MSU crystal deposition, inhibit tophi formation, and accelerate tophi dissolution [59] (Table 2). Halting crystal formation and dissolving existing crystals is the only way to permanently stop the signs and symptoms of gout, and potentially cure the disease [59]. Undertreatment can have significant consequences for a patient, including increased number and frequency of flares, diminished quality of life and productivity,

8 712 G. RUOFF AND N. L. EDWARDS Table 2. Why keep serum uric acid levels <6 mg/dl? Keeping the levels of sua <6 mg/dl, which is below the saturation concentration of 6.8 mg/dl, can help: Prevent MSU crystal formation Prevent inflammation Reduce progressive debilitating joint and tissue damage Reduce the amount of crystals in the body Reduce the likelihood of flares Reduce tophus formation Prevent gouty arthritis Increase dissolution of tophi Keeping levels of sua sufficiently below the saturation concentration of 6.8 mg/dl will mitigate fluctuations in sua levels due to physiologic and natural factors Halting crystal formation and eliminating existing crystals, together, is the only way to stop signs and symptoms of gout MSU: monosodium urate; sua: serum uric acid. and increased use of systemic steroids and nonsteroidal antiinflammatory drugs [20]. Inadequate or delayed treatment and the failure to reduce sua levels <6 mg/dl can result in increased crystal deposition and development of comorbidities, which can in turn result in more severe disease that is more difficult to treat and manage [20,26,63]. Imaging studies have found a close relationship between features of structural joint damage and crystal deposition, with MSU crystals frequently observed within the areas of bone erosion [40]. This close relationship between joint damage and MSU crystal formation emphasizes the need to reduce sua levels before structural damage occurs [26]. A number of studies found that patients experienced fewer flares and better therapeutic outcomes when their sua levels remained at <6 mg/dl [45,64 68]. In one prospective study, sustained reduction of sua levels <6 mg/dl over a 5-year period with long-term febuxostat therapy resulted in nearly complete elimination of gout flares in all patients (N = 116) and total dissolution of tophi in 69% of the patients who had palpable tophi at baseline (Figure 7) [64]. A prospective study of patients with MSU crystal-confirmed gout (N = 18) found that lowering sua to levels <5 mg/dl resulted in disappearance of MSU crystals [66]. The time required for disappearance ranged from 3 to 33 months, and disappearance of crystals took longer in patients who had gout for a longer duration [66]. A retrospective study of 267 patients found that the use of ULT and significant lowering of sua levels reduced the risk of a gout attack over a 3-year period [65]. Another retrospective study, which assessed gout outcomes over a 10-year period in patients with crystal-confirmed gout (N = 38), found that almost half of patients who maintained their sua levels 6 mg/dl for more than 12 months had no gout attacks for 2 or more years [45]. They also found that urate crystal deposition in knees and joint fluids were depleted in more than half (56%) of patients who maintained their sua 6 mg/dl [45]. The effect of reducing sua levels on radiographic changes is less clear. A retrospective study that assessed management of gout over a 10-year period found that tophaceous resorption correlated with serum levels 6 mg/dl [67]. However, they found no correlation between sua levels and radiographic changes [67]. Similarly, another study in patients with early gout treated for 2 years with febuxostat found that treatment greatly reduced synovitis but did not alter joint erosion scores [69]. In contrast, an exploratory study, which evaluated radiographic changes following intensive sua-lowering therapy with pegloticase in patients with severe chronic gout, found that sustaining sua levels <1 mg/dl for 1 year resulted in improvement in structural changes, particularly bone erosion, suggesting that some structural damage may be reversible [68]. A key difference in these studies is the Figure 7. Percentage of patients who required treatment for flares while receiving a maintenance dose of febuxostat to keep sua levels <6 mg/dl. Reproduced with permission from Schumacher HR, Jr., et al: Rheumatology (Oxford) 2009;48(2): [64].

9 POSTGRADUATE MEDICINE 713 degree of uric acid suppression by different medical regimens, and this is the likely explanation for the different outcomes. Although the disease is well understood, with good treatment options available, gout is often poorly managed [28,70]. Challenges of treating and managing gout include physician adherence to recommended guidelines when prescribing, and patient adherence to their prescribed treatment regimens [71,72]. In a retrospective study of 9482 patients with gout enrolled in managed care, only 18% of patients who filled at least two prescriptions were compliant with their allopurinol therapy throughout a 2-year study period [73]. Another study found that of 4166 patients who initiated ULT for gout, more than 50% were nonadherent with their treatment, particularly younger patients (<50 years of age), patients with fewer comorbidities, and those with no visits to a healthcare provider prior to gout [72]. These findings point out the importance of proactive education of patients about their disease [74]. Patient education has been found to improve adherence, reduce the number of attacks, and improve the number of patients who reach sua target levels [74]. Rheumatologists and PCPs have also been found to have less than optimal overall adherence to treatment guidelines, particularly for first-line ULT and length of prophylactic treatment [71,75]. For example, a comprehensive quantitative survey that assessed adherence of US PCPs (n = 120) and rheumatologists (n = 71) to the ACR guidelines found that 53.7% of PCPs and 35.3% of rheumatologists had low adherence to treatment recommendations (defined as following 4 out of 8 ACR treatment recommendations), and even among highly adherent PCPs and rheumatologists, only 36.4% and 35.2%, respectively, were adherent to the initial ULT dose [71]. Conclusions Gout is a chronic, pervasive disease characterized by underlying hyperuricemia that results in recurrent flares and MSU crystal deposition. Even when patients are asymptomatic and free from flares, ongoing inflammation and subsequent damage occur locally at the joint and systemically [26,76]. Several guidelines recommend targets for sua levels <6 mg/dl to prevent MSU crystal deposition, reduce the overall volume of crystals in the body, and dissolve tophi [31,53,56 58,77]. Halting crystal formation and hastening dissolution of existing crystals are key to preventing the long-term negative effects of gout on a patient s health and quality of life [2,52]. Importantly, only by keeping the sua level <6 mg/dl can disease progression be halted and therapeutic outcomes improved [13,59,64,65,78,79]. While hyperuricemia is defined at sua >6.8 mg/dl, the target goal of <6 mg/dl provides a necessary margin to mitigate the effects of fluctuations in factors that can influence the concentration and solubility of sua. Physician and patient education is also key for properly managing the disease to ensure medication compliance and regular (6 12 months) monitoring of sua levels. About two-thirds of gout patients in the USA are diagnosed and managed by PCPs [80,81]. Hence, these healthcare professionals can make a significant impact on treating this disease by ensuring that after gout diagnosis more patients receive optimal care [28]. With proper titration and dosing of medication, regular sua monitoring, and patient compliance, gout is a curable disease [59,82]. The old treat-to-symptoms approach for managing gout is in large part responsible for the historically poor management of this disease. By contrast, the treat-to-target recommendation of guidelines from multiple professional organizations [28,31,53 55,58,77] is based on clear and consistent demonstration that this approach improves long-term outcomes in this common disease. Funding This study was funded by AstraZeneca. Declaration of interest Support for this paper was provided by AstraZeneca Pharmaceuticals, and editorial assistance was provided by Charlotte Singh, MD, CMPP, and Elizabeth Goodwin, PhD, of The Lockwood Group. NL Edwards has been a consultant for Takeda, AstraZeneca, Crealta/Horizon, and CymaBay Pharmaceuticals. G Ruoff has served on the advisory boards and speakers bureaus for Takeda, Endo, and Cephalon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. References 1. CDC. Arthritis: Gout [cited 2015 Aug 27]. Available from: 2. Saccomano SJ, Ferrara LR. Treatment and prevention of gout. Nurse Pract. 2015;40(8): Edwards NL. Crystal deposition diseases. In: Goldman L, Schafer AI, editors. Goldman s cecil medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; p McQueen FM, Reeves Q, Dalbeth N. New insights into an old disease: advanced imaging in the diagnosis and management of gout. Postgrad Med J. 2013;89(1048): Scott JT. New knowledge of the pathogenesis of gout. J Clin Pathol Suppl (R Coll Pathol). 1978;12: Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey Arthritis Rheum. 2011;63(10): CDC. Fibromyalgia. [cited 2015 Sep 8]. Available from: cdc.gov/arthritis/basics/fibromyalgia.htm. 8. Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006;56(1): Liu JT, Yeh HM, Liu SY, et al. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop. 2014;5(4): Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25(6): Edwards NL, Sundy JS, Forsythe A, et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1): Strand V, Khanna D, Singh JA, et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39(7): Becker MA, Schumacher HR, Benjamin KL, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5): Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48(Suppl 2):ii2 ii Richette P, Bardin T. Gout. Lancet. 2010;375(9711):

10 714 G. RUOFF AND N. L. EDWARDS 16. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1): Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52(1): Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364(5): Soltani Z, Rasheed K, Kapusta DR, et al. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013;15 (3): Baker JF, Schumacher HR. Update on gout and hyperuricemia. Int J Clin Pract. 2010;64(3): Li R, Miao L, Qin L, et al. A meta-analysis of the associations between the Q141K and Q126X ABCG2 gene variants and gout risk. Int J Clin Exp Pathol. 2015;8(9): MacFarlane LA, Kim SC. Gout: a review of nonmodifiable and modifiable risk factors. Rheum Dis Clin North Am. 2014;40(4): Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(Suppl 1):S Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8): Hench PS. Diagnosis and treatment of gout and gouty arthritis. JAMA. 1941;116(6): Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther. 2015;32(1): Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73(9): Hamburger M, Baraf HS, Adamson TC 3rd, et al. Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6Suppl 1): Becker MA. Arthritis and allied conditions. 14th ed. Philadelpia, PA: Lippincott Williams & Wlikins; p Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10): Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65 (10): Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6): Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3): Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26(2): Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res. 2011;4(1): Neogi T, Jansen TL, Dalbeth N, et al. Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74 (10): Puig JG, de Miguel E, Castillo MC, et al. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids. 2008;27(6): Pascual E, Batlle-Gualda E, Martínez A, et al. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131 (10): Carter JD, Kedar RP, Anderson SR, et al. An analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographs. Rheumatology (Oxford). 2009;48(11): Chowalloor PV, Siew TK, Keen HI. Imaging in gout: A review of the recent developments. Ther Adv Musculoskelet Dis. 2014;6 (4): Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2): Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006;8(Suppl 1):S Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis. 1983;42(Suppl 1): Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12(2): Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28(3): Agudelo CA, Wise CM. Crystal-associated arthritis. Clin Geriatr Med. 1998;14(3): Terkeltaub R, Edwards NL. Chapter 6. In: Terkeltaub R, Edwards NL, editors. Gout: diagnosis and management of gouty arthritis and hyperuricemia. 3rd ed. Durant (OK): Professional Communications; Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29(7): Keenan RT, Nowatzky J, Pillinger MH. Etiology and pathogenesis of hyperuricemia and gout. In Kelley s textbook of rheumatology, 9th ed. 2013; Philadelphia, PA: Elsevier. 50. So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120(6): Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13): Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48(Suppl 2):ii9 ii Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10): Richette P, Doherty M, Pascual E, et al. [SAT0531] Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2014;73(Suppl2): Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2): Yamanaka H. Revised version of guideline for the management of hyperuricemia and gout. Nihon Rinsho. 2008;66(4): Romeijnders AC, Gorter KJ. Summary of the Dutch college of general practitioners Gout standard. Ned Tijdschr Geneeskd. 2002;146(7): Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8): Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4): Richette P, Frazier A, Bardin T. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol. 2015;27(2): Gasparyan AY, Ayvazyan L, Yessirkepov M, et al. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol. 2015;11(11): Holland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J. 2015;45(2): Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20(2):

11 POSTGRADUATE MEDICINE Schumacher HR Jr., Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2): Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3): Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007;66(8): McCarthy GM, Barthelemy CR, Veum JA, et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum. 1991;34(12): Dalbeth N, Doyle A, McQueen FM, et al. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy. Arthritis Care & Research. 2012;66(1): Dalbeth N, Saag KG, Palmer W, et al. Imaging and safety assessments following treatment with febuxostat and placebo for 2 years in subjects with early gout [abstract]. Arthritis & Rheumatism. 2015;67(Suppl 10). Abstract no Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011;13(2): Oderda GM, Shiozawa A, Walsh M, et al. Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med. 2014;126(3): Edwards RR, Wasan AD, Bingham CO, et al. Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31(8): Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6): Harrold LR, Mazor KM, Negron A, et al. Primary care providers knowledge, beliefs and treatment practices for gout: results of a physician questionnaire. Rheumatology (Oxford). 2013;52(9): Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8(Suppl 1):S Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3): Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34(9): Chandratre P, Roddy E, Clarson L, et al. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52 (11): Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3): Singh JA, Sarkin A, Shieh M, et al. Health care utilization in patients with gout. Semin Arthritis Rheum. 2011;40(6): Wortmann RL. Effective management of gout: an analogy. Am J Med. 1998;105(6):

Uloric Step Therapy Program

Uloric Step Therapy Program Uloric Step Therapy Program Policy Number: 5.01.584 Last Review: 7/2017 Origination: 7/2014 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for brand

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other PEGLOTICASE KRYSTEXXA 37154 GUIDELINES FOR USE 1. Does the patient have a diagnosis of symptomatic chronic gout (prior to initiating Krystexxa therapy) with clinical

More information

1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout

1. To review the diagnosis of gout and its differential. 2. To understand the four stages of gout Objectives 1. To review the diagnosis of gout and its differential GOUT 2. To understand the four stages of gout 3. To develop an approach for the acute treatment of gout Anthony Lim 9/13/12 Cycle 3 4.

More information

Rheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy

Rheumatoid arthritis, seronegative spondylarthritides and gout. György Nagy Rheumatoid arthritis, seronegative spondylarthritides and gout György Nagy Dec 4, 2017 Rheumatoid arthritis Rheumatoid arthritis Chronic, progressive, autoimmune disorder of the joints with extra-articular

More information

Gout Hanan Abdel Rehim

Gout Hanan Abdel Rehim Review article 35 Gout Hanan Abdel Rehim Department of Internal Medicine, Kasr-Al Aini School of Medicine, Cairo University, Cairo, Egypt Correspondence to Hanan Abdel Rehim, MD, 11 Ismaiel Wahby Street,

More information

Rheumatology Cases for the Internist

Rheumatology Cases for the Internist Rheumatology Cases for the Internist Marc C. Hochberg, MD, MPH Professor of Medicine Head, Division of Rheumatology and Clinical Immunology Vice Chair, Department of Medicine University of Maryland School

More information

Gout -revisited. Shrenik Shah

Gout -revisited. Shrenik Shah Gout -revisited Shrenik Shah definition Monosodium urate (MSU) crystal deposition episodic and later persistent joint inflammation and tophi All MSU crystal deposition- broader definition EULAR- European

More information

Gout A rapid review. Jeremy Jones

Gout A rapid review. Jeremy Jones Gout A rapid review Jeremy Jones The Hyperuricemia Cascade Dietary purines Tissue nucleic acids Urate Endogenous purine synthesis Overproduction Hyperuricemia Underexcretion Silent tissue deposition Gout

More information

A Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C.

A Patient s Guide to Gout. Foot and Ankle Center of Massachusetts, P.C. A Patient s Guide to Gout Welcome to Foot and Ankle Center of Massachusetts, where we believe in accelerating your learning curve with educational materials that are clearly written and professionally

More information

Long-term Treatment of Gout: New Opportunities for Improved Outcomes

Long-term Treatment of Gout: New Opportunities for Improved Outcomes Long-term Treatment of Gout: New Opportunities for Improved Outcomes Paul P. Doghramji, MD, FAAFP CONTINUING MEDICAL EDUCATION LEARNING OBJECTIVES Make a presumptive diagnosis of gout based on history

More information

Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs Reinders, Mattheus Karsien

Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs Reinders, Mattheus Karsien University of Groningen Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs Reinders, Mattheus Karsien IMPORTANT NOTE: You are advised to consult the publisher's version

More information

Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP

Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Achieving Gout Goals in Your Practice An Interview with Paul P. Doghramji, MD, FAAFP Dr. Paul Doghramji is attending physician at the Pottstown Memorial Medical Center and medical director of Health Services

More information

MEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011

MEDICAL POLICY PEGLOTICASE (KRYSTEXXA ) POLICY NUMBER MP POLICY TITLE. Original Issue Date (Created): January 1, 2011 Original Issue Date (Created): January 1, 2011 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY PREAUTHORIZATION REQUIRED Note: Requests for pegloticase

More information

GOUT. Dr Krishnan Baburaj West herts NHS Trust

GOUT. Dr Krishnan Baburaj West herts NHS Trust GOUT Dr Krishnan Baburaj West herts NHS Trust podagra Gout A disease of kings, the king of diseases History Louis XIV Emperor Augustus Henry VIII Introduction Gout an inflammatory arthritic condition that

More information

COPYRIGHT. Update in Internal Medicine December 4, 2016

COPYRIGHT. Update in Internal Medicine December 4, 2016 Update in Internal Medicine December 4, 2016 Fadi Badlissi, MD, MSc Director of the Musculoskeletal Medicine Unit The Orthopedic Department & Rheumatology Division Beth Israel Deaconess Medical Center

More information

Gout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy

Gout 2.0. Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Gout 2.0 Scott Vogelgesang, M.D. Division of Immunology: Rheumatology & Allergy Case 48 year old man presents with swollen, painful left toe that started overnight. Didn t hurt when he went to bed. No

More information

Gout in the UK and Germany: prevalence, comorbidities and management in general practice

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 1 IMS Health, Brussels, Belgium; 2 Department of Public Health, Ghent University, Ghent, Belgium; 3 School of Pharmacy, Brussels University, Brussels, Belgium; 4 IMS Health, London, UK; 5 Ipsen, Paris,

More information

Crystal-Induced Arthritis. Rajesh Kataria, D.O. Southern Ohio Rheumatology

Crystal-Induced Arthritis. Rajesh Kataria, D.O. Southern Ohio Rheumatology Crystal-Induced Arthritis Rajesh Kataria, D.O. Southern Ohio Rheumatology Disclosures Speaker: Rajesh Kataria, D.O. Relationships with commercial interests: Speakers Bureau - Horizon Presentation will

More information

Disclosures. Ultrasonography. Conventional radiography (XR) Magnetic resonance imaging. Conventional CT 10/27/2013

Disclosures. Ultrasonography. Conventional radiography (XR) Magnetic resonance imaging. Conventional CT 10/27/2013 What I can see in my gout patient that I couldn t before: the role of advanced imaging in gout diagnosis and monitoring Disclosures ND is supported by the Health Research Council of New Zealand I have

More information

Crystal induced arthropathies. Dr. Amitesh Aggarwal

Crystal induced arthropathies. Dr. Amitesh Aggarwal Crystal induced arthropathies Dr. Amitesh Aggarwal 1 Crystal induced Arthropathies Gout Pseudogout Debilitating illnesses; Recurrent episodes of pain and joint inflammation; Formation and deposition of

More information

Gout basics. Update on Gout. Production of uric acid. Gout basics. Crystal induced inflammation. Gout calculator. The important role of ultrasound

Gout basics. Update on Gout. Production of uric acid. Gout basics. Crystal induced inflammation. Gout calculator. The important role of ultrasound Update on Gout The important role of ultrasound Cheung C Yue, M.D. Gout basics Hyperuricemia gout Over 5 years, 22% >9 mg/dl develop gout Man 3-4 times more than women Risks: thiazide, cyclosporin, low

More information

ARD Online First, published on November 2, 2007 as /ard

ARD Online First, published on November 2, 2007 as /ard ARD Online First, published on November 2, 2007 as 10.1136/ard.2007.076232 Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000 2005 L Annemans, E Spaepen, M Gaskin,

More information

Clinical Practice Guideline. Gout. Version

Clinical Practice Guideline. Gout. Version Clinical Practice Guideline Gout Version 1.1.2017 August 2017 Table of Contents Introduction...5 Stages of Gout...7 Asymptomatic Hyperuricemia... 7 Acute Intermittent Gout... 7 Advanced Gout... 8 Diagnosis...8

More information

Treating to target: a strategy to cure gout

Treating to target: a strategy to cure gout Rheumatology 2009;48:ii9 ii14 doi:10.1093/rheumatology/kep087 Treating to target: a strategy to cure gout Fernando Perez-Ruiz 1 Acute gout attacks and the long-term complications of gout are associated

More information

CHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:2 GOUT. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:2 GOUT BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY DEFINITION Gout is defined as a peripheral arthritis, resulting from the deposition of MSU crystals

More information

An update on the management of gout

An update on the management of gout An update on the management of gout 8 The management of gout involves treatment of an acute attack, lifestyle modification and urate lowering treatment to achieve a target serum urate level. Recent evidence

More information

Gout: Update in therapeutics

Gout: Update in therapeutics Summary Gout: Update in therapeutics 29/11/14 Caroline van Durme CHU de Liège Maastricht University Medical Centre+ Why treating gout? Guidelines: ACR 12 Drugs: Colchicine Allopurinol: what about the kidney?

More information

OBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE

OBJECTIVES GOUT GOUTY INFLAMMATION 6/10/2016 GOUT INCIDENCE AND PREVALENCE MONOSODIUM URATE CRYSTAL DEPOSITION DISEASE GOUT Lisa Talbert, MD Family Medicine Update June 15, 2016 OBJECTIVES To be familiar with the clinical presentation and pathophysiology of gouty arthritis Be able to incorporate current guidelines when

More information

Gout. Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 CLINICAL REVIEW

Gout. Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 CLINICAL REVIEW Gout Edward Roddy, 1 Christian D Mallen, 1 Michael Doherty 2 1 Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, Keele ST5 5BG, UK 2 Academic Rheumatology, University

More information

Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout

Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.

More information

GOUT & PSEUDOGOUT OPSC 2018 HOWARD L. FEINBERG, D.O., F.A.C.O.I.., F.A.C.R.

GOUT & PSEUDOGOUT OPSC 2018 HOWARD L. FEINBERG, D.O., F.A.C.O.I.., F.A.C.R. GOUT & PSEUDOGOUT OPSC 2018 HOWARD L. FEINBERG, D.O., F.A.C.O.I.., F.A.C.R. Everything in excess is opposed by nature Eunuchs do not take the gout, nor become bald. GOUT Hyperuricemia is not gout Gout

More information

COMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT

COMPARATIVE EVALUATION OF EFFICACY AND SAFETY PROFILE OF FEBUXOSTAT WITH ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND GOUT Int. J. Pharm. Med. & Bio. Sc. 2013 P K Agarwal and Bijay Kumar, 2013 Research Paper ISSN 2278 5221 www.ijpmbs.com Vol. 2, No. 4, October 2013 2013 IJPMBS. All Rights Reserved COMPARATIVE EVALUATION OF

More information

pegloticase (Krystexxa )

pegloticase (Krystexxa ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Essence of the Revised Guideline for the Management of Hyperuricemia and Gout

Essence of the Revised Guideline for the Management of Hyperuricemia and Gout Research and Reviews Essence of the Revised Guideline for the Management of Hyperuricemia and Gout JMAJ 55(4): 324 329, 2012 Hisashi YAMANAKA,* 1 The Guideline Revising Committee of Japanese Society of

More information

Gout and Hyperuricemia

Gout and Hyperuricemia Gout and Hyperuricemia 100 Access publication Sep. 2016 Computed tomography manifestation of gouty arthritis Hu Yabin 1, Yang Qing 1, Cao Qiang 2, Ren Jianan 1, Yang Qing * Objective: Of the most commonly

More information

Case presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg

Case presentation. serum uric acid = 11.5 mg/dl 24-hour uric acid excretion = 300 mg GOUT 55 y/o male 12 hours pain in my big toe & ankle went to bed last night feeling fine felt as if had broken toe this morning similar problems in right ankle & left wrist Case presentation lab studies

More information

Update on Gout for GPs

Update on Gout for GPs Update on Gout for GPs Dr Patrick Kiely PhD FRCP Consultant Physician and Rheumatologist St George s, London 2/3 1/3 Gut bacteria have uricase Chronic erosive arthropathy Clinical spectrum Making the diagnosis

More information

Diagnosis and Management of Gout in 2011

Diagnosis and Management of Gout in 2011 October 18, 2011 Early and accurate gout diagnosis and disease management are essential. Making the clinical diagnosis takes into consideration the differential diagnosis supported by the use of clinical,

More information

Role of diagnostic ultrasonography in detecting gouty arthritis

Role of diagnostic ultrasonography in detecting gouty arthritis The Egyptian Rheumatologist (2013) 35, 71 75 Egyptian Society for Joint Diseases and Arthritis The Egyptian Rheumatologist www.rheumatology.eg.net www.sciencedirect.com ORIGINAL ARTICLE Role of diagnostic

More information

Hyperuricemia and Gout: A Prevalent and Chronic Disease

Hyperuricemia and Gout: A Prevalent and Chronic Disease Hyperuricemia and Gout: Clinical Implications and Treatment Challenges of a Chronic Disease Release date: January, 2005 Expiration date: January, 2006 CME credit: 1 hour, category 1 Hyperuricemia and Gout:

More information

Gout. Crystal deposition disease: Imaging perspectives. Crystal associated arthropathies. Clinical Stages of Gout 07/06/60

Gout. Crystal deposition disease: Imaging perspectives. Crystal associated arthropathies. Clinical Stages of Gout 07/06/60 Crystal associated arthropathies Crystal deposition disease: Imaging perspectives Warapat Virayavanich, MD Ramathibodi hospital, Mahidol University Commonly seen arthropathy MSU (gout) CPPD HADD Uncommon

More information

Journal of Advanced Scientific Research

Journal of Advanced Scientific Research Bijoy Kumar Panda et al, J Adv Scient Res, 2012, 3(2): 03-11 3 Journal of Advanced Scientific Research Available online through http://www.sciensage.info/jasr ISSN 0976-9595 Review Article Febuxostat,

More information

Krystexxa (pegloticase) Document Number: IC-0158

Krystexxa (pegloticase) Document Number: IC-0158 Krystexxa (pegloticase) Document Number: IC-0158 Last Review Date: 06/27/2017 Date of Origin: 02/07/20103 Dates Reviewed: 11/2013, 08/2014, 07/2015, 07/2016, 09/2016, 12/2016, 03/2017, 06/2017 I. Length

More information

Gout Treatment Guidelines

Gout Treatment Guidelines Gout Treatment Guidelines Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia,

More information

Gout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting

Gout. Clinical features Most commonly affects middle-aged males. It is an acute and usually relapsing selflimiting Gout Gout is a syndrome caused by an inflammatory response to the formation of monosodium urate monohydrate crystals which develop secondary to hyperuricemia. Acute and chronic forms are recognized. Hyperuricemia

More information

Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout

Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with

More information

Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam. Howard J. Sachs, MD

Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam. Howard J. Sachs, MD Podcast (Video Recorded Lecture Series): Gout for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded Lecture Series): Gout for the

More information

Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study

Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study Research Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study Robert D Goldfien, 1 Michele S Ng, 2 Goldie Yip, 2 Alice Hwe, 2

More information

MONOSODIUM URATE CRYSTALS IN THE KNEE JOINTS OF PATIENTS WITH ASYMPTOMATIC NONTOPHACEOUS GOUT

MONOSODIUM URATE CRYSTALS IN THE KNEE JOINTS OF PATIENTS WITH ASYMPTOMATIC NONTOPHACEOUS GOUT 148 MONOSODIUM URATE CRYSTALS IN THE KNEE JOINTS OF PATIENTS WITH ASYMPTOMATIC NONTOPHACEOUS GOUT JOHN S. BOMALASKI, GERONIMO LLUBERAS, and H. RALPH SCHUMACHER, JR. We aspirated synovial fluid from the

More information

New Drug Evaluation: lesinurad tablet, oral

New Drug Evaluation: lesinurad tablet, oral Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

A case of extensive synovial involvement by tophaceous gout

A case of extensive synovial involvement by tophaceous gout A case of extensive synovial involvement by tophaceous gout Nausheen Khan, MB BS, FCRad (D) Irma van de Werke, MB ChB, FRCR Farzanah Ismail, MB ChB, FCRad (D) Department of Radiology, Kalafong Hospital,

More information

Supplementary Material*

Supplementary Material* Supplementary Material* Newberry SJ, FitzGerald JD, Motala A, Booth M, Maglione MA, Han D, Tariq A, O Hanlon CE, Shanman R, Dudley W, Shekelle PG. Diagnosis of gout. A systematic review in support of an

More information

Ultrasonography in gout: a case-control study

Ultrasonography in gout: a case-control study Ultrasonography in gout: a case-control study S. Ottaviani, P. Richette, A. Allard, J. Ora, T. Bardin Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, and AP-HP, Service de Rhumatologie,

More information

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial BRIEF OBSERVATION Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial Thomas H. Taylor, MD, a,b,c John N. Mecchella, DO, b,c Robin J. Larson, MD, a,b

More information

Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices

Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Implementing AHRQ Effective Health Care Reviews Helping Clinicians Make Better Treatment Choices Gout: Diagnosis and Management Practice Pointers by MATTHEW R. NOSS, DO, MSEd, U.S. Army Health Clinic,

More information

New insights into an old disease: advanced imaging in the diagnosis and management of gout

New insights into an old disease: advanced imaging in the diagnosis and management of gout 1 Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand 2 Department of Radiology, Auckland City Hospital and Specialist Radiology and MRI, Auckland, New Zealand

More information

Radiologic manifestations of gout in MRI

Radiologic manifestations of gout in MRI Radiologic manifestations of gout in MRI Poster No.: C-1053 Congress: ECR 2012 Type: Authors: Keywords: DOI: Educational Exhibit D. Gorostiza Laborda, A. Urresola Olabarrieta, B. Canteli Padilla, F. Perez-Ruiz,

More information

Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.

Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved. 14 The Nurse Practitioner Vol. 41, No. 14 www.tnpj.com 2.5 CONTACT HOURS 2.5 CONTACT HOURS Gout An update on for primary care providers Abstract: This article discusses the current beliefs regarding the

More information

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases Rheumatol Ther (2018) 5:583 594 https://doi.org/10.1007/s40744-018-0111-9 CASE SERIES Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases Allan H. Morton.

More information

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016

Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Gout and Pseudogout Wayne Blount MD Speaker has no disclosures

More information

Long-term safety of pegloticase in chronic gout refractory to conventional treatment

Long-term safety of pegloticase in chronic gout refractory to conventional treatment University of Massachusetts Medical School escholarship@umms Meyers Primary Care Institute Publications and Presentations Meyers Primary Care Institute 11-10-2012 Long-term safety of pegloticase in chronic

More information

Enhanced Primary Care Pathway: Gout

Enhanced Primary Care Pathway: Gout Enhanced Primary Care Pathway: Gout 1. Focused summary of gout relevant to primary care Significance: Gout is a chronic, progressive, inflammatory disease requiring appropriate long-term management. Gout

More information

Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment

Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor

More information

Gout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA

Gout- Treatment Updates. Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout- Treatment Updates Harinder Singh, MD Rheumatology Mercy Internal Medicine Clinic Mason City, IA Gout Outline of purine metabolism: (1) amidophosphoribosyltransferase (2) hypoxanthine-guanine phosphoribosyltransferase

More information

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal

More information

Febuxostat: a new treatment for hyperuricaemia in gout

Febuxostat: a new treatment for hyperuricaemia in gout Rheumatology 2009;48:ii15 ii19 doi:10.1093/rheumatology/kep088 Febuxostat: a new treatment for hyperuricaemia in gout N. Lawrence Edwards 1 Febuxostat is a new non-purine xanthine oxidase inhibitor that

More information

Gouty arthritis: an approach for general practice

Gouty arthritis: an approach for general practice Gouty arthritis: an approach for general practice Abstract Tikly M, MBBCh, PhD, FCP(SA), FRCP, Professor of Rheumatology Makan K, MBChB, FCP(SA), Rheumatology Fellow Division of Rheumatology, Chris Hani

More information

Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s):

Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13. Policy Number: MCP-138. Revision Date(s): Subject: Krystexxa (pegloticase) Original Effective Date: 06/26/13 Policy Number: MCP-138 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP) is

More information

University of Groningen

University of Groningen University of Groningen Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients Reinders, M.K.; van Roon, Eric; Houtman, Pieternella; Brouwers,

More information

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Handling editor Tore K Kvien Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ annrheumdis-2015-208237) For numbered affiliations see end

More information

Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort

Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort Rheumatol Ther (2017) 4:419 425 DOI 10.1007/s40744-017-0082-2 ORIGINAL RESEARCH Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis

More information

Objectives: To assess the distribution of bone erosions in the feet of patients

Objectives: To assess the distribution of bone erosions in the feet of patients Gout on CT: a symmetric arthropathy. Anthony J Doyle (corresponding author) Objectives: To assess the distribution of bone erosions in the feet of patients with gout using computed tomography (CT) and

More information

Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia

Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia Reuss-Borst et al. SpringerPlus 2014, 3:592 a SpringerOpen Journal RESEARCH Open Access Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia Monika A Reuss-Borst

More information

Acute hot swollen joint. Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist

Acute hot swollen joint. Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist Acute hot swollen joint Dr Edward Roddy Senior Lecturer in Rheumatology and Consultant Rheumatologist Acute monoarthritis: differential diagnosis Septic arthritis Crystal arthritis (gout, pseudogout) Haemarthrosis

More information

Class Update: Drugs for Gout

Class Update: Drugs for Gout Copyright 2012 Oregon State University. ll Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

GOUT IN THE ELDERLY. Learning Objectives. Disclosure. Geriatric Grand Rounds. Geriatric Grand Rounds

GOUT IN THE ELDERLY. Learning Objectives. Disclosure. Geriatric Grand Rounds. Geriatric Grand Rounds Visit web sites: Tuesday, June 2, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this event

More information

Effectiveness of a pharmacist-based gout care management program in a large integrated health plan: Results from a pilot study For peer review only

Effectiveness of a pharmacist-based gout care management program in a large integrated health plan: Results from a pilot study For peer review only BMJ Open Effectiveness of a pharmacist-based gout care management program in a large integrated health plan: Results from a pilot study Journal: BMJ Open Manuscript ID: bmjopen--00 Article Type: Research

More information

3/2/2014. Got Gout? Get a Plumber. Objectives. Disclosures

3/2/2014. Got Gout? Get a Plumber. Objectives. Disclosures Got Gout? Get a Plumber. Heidi Garcia, PA-C Department of Rheumatology Division of Internal Medicine Mayo Clinic Arizona 2013 MFMER slide-1 Objectives Recall some of the history of Gout. Describe the pathophysiology

More information

Clinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective Observational Study

Clinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective Observational Study International Rheumatology, Article ID 123105, 6 pages http://dx.doi.org/10.1155/2014/123105 Clinical Study Urate Lowering Therapy with Febuxostat in Daily Practice A Multicentre, Open-Label, Prospective

More information

Tophus resolution in patients with chronic refractory gout who have persistent uratelowering responses to pegloticase

Tophus resolution in patients with chronic refractory gout who have persistent uratelowering responses to pegloticase Mandell et al. Arthritis Research & Therapy (2018) 20:286 https://doi.org/10.1186/s13075-018-1782-x RESEARCH ARTICLE Tophus resolution in patients with chronic refractory gout who have persistent uratelowering

More information

Patients' knowledge and beliefs concerning gout and its treatment: a population based study

Patients' knowledge and beliefs concerning gout and its treatment: a population based study University of Massachusetts Medical School escholarship@umms Meyers Primary Care Institute Publications and Presentations Meyers Primary Care Institute 9-21-2012 Patients' knowledge and beliefs concerning

More information

Novel uricosurics RHEUMATOLOGY. Thomas Bardin 1,2 and Pascal Richette 1,2. Abstract. Introduction REVIEW

Novel uricosurics RHEUMATOLOGY. Thomas Bardin 1,2 and Pascal Richette 1,2. Abstract. Introduction REVIEW RHEUMATOLOGY Rheumatology 2018;57:i42 i46 doi:10.1093/rheumatology/kex433 Novel uricosurics Thomas Bardin 1,2 and Pascal Richette 1,2 REVIEW Abstract Objective. According to recent guidelines, the mainstay

More information

Outcome Measures for Gout Clinical Trials: a Summary of Progress Hugh de Lautour, MBChB 1,* Nicola Dalbeth, FRACP 1,2 William J. Taylor, PhD, MBChB 3

Outcome Measures for Gout Clinical Trials: a Summary of Progress Hugh de Lautour, MBChB 1,* Nicola Dalbeth, FRACP 1,2 William J. Taylor, PhD, MBChB 3 Curr Treat Options in Rheum (2015) 1:156 166 DOI 10.1007/s40674-015-0014-7 Gout (A Gibofsky, Section Editor) Outcome Measures for Gout Clinical Trials: a Summary of Progress Hugh de Lautour, MBChB 1,*

More information

Gout: A Clinical Update. Why talk about Gout? Why talk about Gout? Populations at risk: Why is Gout Less Common in Women? US Gout Population: 2009

Gout: A Clinical Update. Why talk about Gout? Why talk about Gout? Populations at risk: Why is Gout Less Common in Women? US Gout Population: 2009 Gout: A Clinical Update Peng Thim Fan, MD, FACP Clinical Professor of Medicine Division of Rheumatology David Geffen School of Medicine at UCLA Why talk about Gout? Large increase in gout in the last 20

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Krystexxa) Reference Number: CP.PHAR.115 Effective Date: 06.01.13 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

Gout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017

Gout: Let s Be Crystal Clear. Dr. Philip A. Baer Seacourses Asia CME December 2017 Gout: Let s Be Crystal Clear Dr. Philip A. Baer Seacourses Asia CME December 2017 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or

More information

2.0. Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. 24 The Nurse Practitioner Vol. 40, No. 8

2.0. Copyright 2015 Wolters Kluwer Health, Inc. All rights reserved. 24 The Nurse Practitioner Vol. 40, No. 8 2.0 CONTACT HOURS 24 The Nurse Practitioner Vol. 40, No. 8 www.tnpj.com Treatment and gout prevention of o leva Abstract: Gout is a disorder of purine metabolism that primarily occurs in adult males. Elevated

More information

THE BURDEN OF SUBCLINICAL SYNOVITIS IN GOUT

THE BURDEN OF SUBCLINICAL SYNOVITIS IN GOUT THE BURDEN OF SUBCLINICAL SYNOVITIS IN GOUT PRIYA CHOWALLOOR, MBBS, FRACP This thesis is presented for the degree of Masters of Clinical Research of The University of Western Australia SCHOOL OF MEDICINE

More information

Crystal Deposition Disease and Psoriatic Arthritis

Crystal Deposition Disease and Psoriatic Arthritis 74 Crystal Deposition Disease and Psoriatic Arthritis Philip J. O Connor, MRCP, FRCR, FFSEM (UK) 1,2 1 Department of Radiology, Leeds Teaching Hospitals, Chapel Allerton Hospital, Leeds, United Kingdom

More information

D espite reasonable understanding of its pathogenesis

D espite reasonable understanding of its pathogenesis 1312 EXTENDED REPORT EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics

More information

Managing Gout A Review of the Research for Adults

Managing Gout A Review of the Research for Adults Managing Gout A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional* has said that you have gout. You are age 18 or

More information

Horizon Pharma plc. KRYSTEXXA ACR Investor Call. November 9, 2017

Horizon Pharma plc. KRYSTEXXA ACR Investor Call. November 9, 2017 Horizon Pharma plc KRYSTEXXA ACR Investor Call November 9, 2017 Forward Looking Statements This presentation contains forward looking statements, including, but not limited to, statements related to Horizon

More information

Spondyloarthritis: A Gouty Display

Spondyloarthritis: A Gouty Display Spondyloarthritis: A Gouty Display Preetam Gongidi 1*, Shawn Gough-Fibkins 2 1. Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, USA 2. Broward General Medical Center,

More information

Dual energy CT in diagnosis of Gout

Dual energy CT in diagnosis of Gout Dual energy CT in diagnosis of Gout Poster No.: R-0060 Congress: RANZCR ASM 2013 Type: Educational Exhibit Authors: F. Tabatabaie Moghadam, A. Moghaddam, F. Ghazanfari ; 1 1 1 2 2 Brisbane/AU, Melbourne/AU

More information

Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice

Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice https://doi.org/10.1007/s40744-017-0091-1 ORIGINAL RESEARCH Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice Fernando

More information

Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout

Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout Briefing Document for the Arthritis Advisory Committee Meeting Date: 23 October 215 Ardea

More information

Gout is a disease of relatively low prevalence. Clinical, Humanistic, and Economic Outcomes of Gout REPORTS

Gout is a disease of relatively low prevalence. Clinical, Humanistic, and Economic Outcomes of Gout REPORTS Clinical, Humanistic, and Economic Outcomes of Gout Diana I. Brixner, RPh, PhD; and Mei-Jen Ho, PharmD Abstract Gout is a low prevalence disease not often considered by managed care organizations with

More information

2015 ACR/EULAR Gout Classification Criteria

2015 ACR/EULAR Gout Classification Criteria 2015 ACR/EULAR Gout Classification Criteria Published Simultaneously in the October 2015 Issues of A&R and ARD Intent of Gout Classification Criteria To identify, in a standardized manner, a relatively

More information